Roles of matrix metalloproteinases in cancer progression and their pharmacological targeting (Q28298681)

Europe PubMed Central

PubMed publication ID

21087457

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21087457

29 August 2024

author name string

Chrisostomi Gialeli

1

0 references

Achilleas D. Theocharis

2

1 reference

Europe PubMed Central

PubMed publication ID

21087457

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21087457

29 August 2024

language of work or name

English

0 references

publication date

January 2011

0 references

19 November 2010

1 reference

Europe PubMed Central

PubMed publication ID

21087457

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21087457

full work available at URL

29 August 2024

https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1111%2Fj.1742-4658.2010.07919.x

1 reference

https://api.crossref.org/works/10.1111/J.1742-4658.2010.07919.X

https://febs.onlinelibrary.wiley.com/doi/pdf/10.1111/j.1742-4658.2010.07919.x

29 August 2024

1 reference

https://api.crossref.org/works/10.1111/J.1742-4658.2010.07919.X

29 August 2024

0 references

278

0 references

issue

1

0 references

page(s)

16-27

0 references

cites work

Cancer statistics, 2004

1

1 reference

https://api.crossref.org/works/10.1111/J.1742-4658.2010.07919.X

Matrix metalloproteinases: regulators of the tumor microenvironment

29 August 2024

2

1 reference

https://api.crossref.org/works/10.1111/J.1742-4658.2010.07919.X

Matrix metalloproteinases and the regulation of tissue remodelling

29 August 2024

3

1 reference

https://api.crossref.org/works/10.1111/J.1742-4658.2010.07919.X

Matrix metalloproteinases as modulators of inflammation and innate immunity

29 August 2024

4

1 reference

https://api.crossref.org/works/10.1111/J.1742-4658.2010.07919.X

New functions for the matrix metalloproteinases in cancer progression

29 August 2024

5

1 reference

https://api.crossref.org/works/10.1111/J.1742-4658.2010.07919.X

Structure and function of matrix metalloproteinases and TIMPs

29 August 2024

6

1 reference

https://api.crossref.org/works/10.1111/J.1742-4658.2010.07919.X

Matrix metalloproteinases as novel biomarkers and potential therapeutic targets in human cancer

29 August 2024

7

1 reference

https://api.crossref.org/works/10.1111/J.1742-4658.2010.07919.X

Metastatic potential correlates with enzymatic degradation of basement membrane collagen

29 August 2024

8

1 reference

https://api.crossref.org/works/10.1111/J.1742-4658.2010.07919.X

Matrix metalloproteinases at cancer tumor-host interface

29 August 2024

9

1 reference

https://api.crossref.org/works/10.1111/J.1742-4658.2010.07919.X

The ADAMs: signalling scissors in the tumour microenvironment

29 August 2024

10

1 reference

https://api.crossref.org/works/10.1111/J.1742-4658.2010.07919.X

Emerging roles of ADAM and ADAMTS metalloproteinases in cancer.

29 August 2024

11

1 reference

https://api.crossref.org/works/10.1111/J.1742-4658.2010.07919.X

Matrix metalloproteinases and tumor metastasis

29 August 2024

12

1 reference

https://api.crossref.org/works/10.1111/J.1742-4658.2010.07919.X

Human neutrophils uniquely release TIMP-free MMP-9 to provide a potent catalytic stimulator of angiogenesis

29 August 2024

13

1 reference

https://api.crossref.org/works/10.1111/J.1742-4658.2010.07919.X

Plasma MMP1 and MMP8 expression in breast cancer: protective role of MMP8 against lymph node metastasis

29 August 2024

14

1 reference

https://api.crossref.org/works/10.1111/J.1742-4658.2010.07919.X

Collagenase-2 (matrix metalloproteinase-8) plays a protective role in tongue cancer

29 August 2024

15

1 reference

https://api.crossref.org/works/10.1111/J.1742-4658.2010.07919.X

Higher sensitivity of Adamts12-deficient mice to tumor growth and angiogenesis.

29 August 2024

16

1 reference

https://api.crossref.org/works/10.1111/J.1742-4658.2010.07919.X

Invadopodia: specialized cell structures for cancer invasion

29 August 2024

17

1 reference

https://api.crossref.org/works/10.1111/J.1742-4658.2010.07919.X

ADAM 12-S cleaves IGFBP-3 and IGFBP-5 and is inhibited by TIMP-3

29 August 2024

18

1 reference

https://api.crossref.org/works/10.1111/J.1742-4658.2010.07919.X

Matrix metalloproteinase-7 degrades all insulin-like growth factor binding proteins and facilitates insulin-like growth factor bioavailability

29 August 2024

19

1 reference

https://api.crossref.org/works/10.1111/J.1742-4658.2010.07919.X

Targeting epidermal growth factor receptor in solid tumors: critical evaluation of the biological importance of therapeutic monoclonal antibodies.

29 August 2024

20

1 reference

https://api.crossref.org/works/10.1111/J.1742-4658.2010.07919.X

Matrix metalloproteinase-3 releases active heparin-binding EGF-like growth factor by cleavage at a specific juxtamembrane site

29 August 2024

21

1 reference

https://api.crossref.org/works/10.1111/J.1742-4658.2010.07919.X

Distinct roles for ADAM10 and ADAM17 in ectodomain shedding of six EGFR ligands

29 August 2024

22

1 reference

https://api.crossref.org/works/10.1111/J.1742-4658.2010.07919.X

ADAM10 mediates E-cadherin shedding and regulates epithelial cell-cell adhesion, migration, and beta-catenin translocation.

29 August 2024

23

1 reference

https://api.crossref.org/works/10.1111/J.1742-4658.2010.07919.X

The integrin alpha(v)beta8 mediates epithelial homeostasis through MT1-MMP-dependent activation of TGF-beta1

29 August 2024

24

1 reference

https://api.crossref.org/works/10.1111/J.1742-4658.2010.07919.X

CD44 anchors the assembly of matrilysin/MMP-7 with heparin-binding epidermal growth factor precursor and ErbB4 and regulates female reproductive organ remodeling

29 August 2024

26

1 reference

https://api.crossref.org/works/10.1111/J.1742-4658.2010.07919.X

Effects of glycosaminoglycans on proliferation of epithelial and fibroblast human malignant mesothelioma cells: a structure-function relationship

29 August 2024

27

1 reference

https://api.crossref.org/works/10.1111/J.1742-4658.2010.07919.X

Cleavage of CD95 by matrix metalloproteinase-7 induces apoptosis resistance in tumour cells

29 August 2024

28

1 reference

https://api.crossref.org/works/10.1111/J.1742-4658.2010.07919.X

The Fas ligand intracellular domain is released by ADAM10 and SPPL2a cleavage in T-cells

29 August 2024

30

1 reference

https://api.crossref.org/works/10.1111/J.1742-4658.2010.07919.X

Tumor-associated MICA is shed by ADAM proteases

29 August 2024

31

1 reference

https://api.crossref.org/works/10.1111/J.1742-4658.2010.07919.X

Antiapoptotic signalling by the insulin-like growth factor I receptor, phosphatidylinositol 3-kinase, and Akt.

29 August 2024

32

1 reference

https://api.crossref.org/works/10.1111/J.1742-4658.2010.07919.X

Targeted expression of stromelysin-1 in mammary gland provides evidence for a role of proteinases in branching morphogenesis and the requirement for an intact basement membrane for tissue-specific gene expression

29 August 2024

33

1 reference

https://api.crossref.org/works/10.1111/J.1742-4658.2010.07919.X

Proteolytic exposure of a cryptic site within collagen type IV is required for angiogenesis and tumor growth in vivo

29 August 2024

35

1 reference

https://api.crossref.org/works/10.1111/J.1742-4658.2010.07919.X

Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis

29 August 2024

36

1 reference

https://api.crossref.org/works/10.1111/J.1742-4658.2010.07919.X

The degradation of human endothelial cell-derived perlecan and release of bound basic fibroblast growth factor by stromelysin, collagenase, plasmin, and heparanases

29 August 2024

37

1 reference

https://api.crossref.org/works/10.1111/J.1742-4658.2010.07919.X

Basement membrane proteoglycans: modulators Par Excellence of cancer growth and angiogenesis.

29 August 2024

38

1 reference

https://api.crossref.org/works/10.1111/J.1742-4658.2010.07919.X

Regulation of angiostatin production by matrix metalloproteinase-2 in a model of concomitant resistance

29 August 2024

39

1 reference

https://api.crossref.org/works/10.1111/J.1742-4658.2010.07919.X

The generation of endostatin is mediated by elastase

29 August 2024

40

1 reference

https://api.crossref.org/works/10.1111/J.1742-4658.2010.07919.X

Proteoglycans in health and disease: novel roles for proteoglycans in malignancy and their pharmacological targeting.

29 August 2024

41

1 reference

https://api.crossref.org/works/10.1111/J.1742-4658.2010.07919.X

Role of cell surface metalloprotease MT1-MMP in epithelial cell migration over laminin-5.

29 August 2024

42

1 reference

https://api.crossref.org/works/10.1111/J.1742-4658.2010.07919.X

Membrane type-1 matrix metalloproteinase (MT1-MMP) processing of pro-alphav integrin regulates cross-talk between alphavbeta3 and alpha2beta1 integrins in breast carcinoma cells

29 August 2024

43

1 reference

https://api.crossref.org/works/10.1111/J.1742-4658.2010.07919.X

Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits

29 August 2024

44

1 reference

https://api.crossref.org/works/10.1111/J.1742-4658.2010.07919.X

Epilysin (MMP-28) induces TGF-beta mediated epithelial to mesenchymal transition in lung carcinoma cells.

29 August 2024

46

1 reference

https://api.crossref.org/works/10.1111/J.1742-4658.2010.07919.X

Mechanism of TGF-beta signaling to growth arrest, apoptosis, and epithelial-mesenchymal transition

29 August 2024

47

1 reference

https://api.crossref.org/works/10.1111/J.1742-4658.2010.07919.X

Reduction of hyaluronan-CD44-mediated growth, migration, and cisplatin resistance in head and neck cancer due to inhibition of Rho kinase and PI-3 kinase signaling

29 August 2024

48

1 reference

https://api.crossref.org/works/10.1111/J.1742-4658.2010.07919.X

Immune-mediated eradication of tumors through the blockade of transforming growth factor-beta signaling in T cells

29 August 2024

50

1 reference

https://api.crossref.org/works/10.1111/J.1742-4658.2010.07919.X

Enhanced tumor growth and invasiveness in vivo by a carboxyl-terminal fragment of alpha1-proteinase inhibitor generated by matrix metalloproteinases: a possible modulatory role in natural killer cytotoxicity

29 August 2024

51

1 reference

https://api.crossref.org/works/10.1111/J.1742-4658.2010.07919.X

Matrilysin shedding of syndecan-1 regulates chemokine mobilization and transepithelial efflux of neutrophils in acute lung injury.

29 August 2024

52

1 reference

https://api.crossref.org/works/10.1111/J.1742-4658.2010.07919.X

Loss of collagenase-2 confers increased skin tumor susceptibility to male mice.

29 August 2024

53

1 reference

https://api.crossref.org/works/10.1111/J.1742-4658.2010.07919.X

Matrix metalloproteinase inhibitors as anticancer therapeutics.

29 August 2024

54

1 reference

https://api.crossref.org/works/10.1111/J.1742-4658.2010.07919.X

Natural bio-drugs as matrix metalloproteinase inhibitors: new perspectives on the horizon?

29 August 2024

55

1 reference

https://api.crossref.org/works/10.1111/J.1742-4658.2010.07919.X

Inhibition of MMP-1 expression by antisense RNA decreases invasiveness of human chondrosarcoma.

29 August 2024

56

1 reference

https://api.crossref.org/works/10.1111/J.1742-4658.2010.07919.X

siRNA mediated inhibition of MMP-1 reduces invasive potential of a human chondrosarcoma cell line.

29 August 2024

57

1 reference

https://api.crossref.org/works/10.1111/J.1742-4658.2010.07919.X

1.8-A crystal structure of the catalytic domain of human neutrophil collagenase (matrix metalloproteinase-8) complexed with a peptidomimetic hydroxamate primed-side inhibitor with a distinct selectivity profile

29 August 2024

58

1 reference

https://api.crossref.org/works/10.1111/J.1742-4658.2010.07919.X

Marimastat: the clinical development of a matrix metalloproteinase inhibitor

29 August 2024

60

1 reference

https://api.crossref.org/works/10.1111/J.1742-4658.2010.07919.X

Randomized phase III trial of marimastat versus placebo in patients with metastatic breast cancer who have responding or stable disease after first-line chemotherapy: Eastern Cooperative Oncology Group trial E2196

29 August 2024

61

1 reference

https://api.crossref.org/works/10.1111/J.1742-4658.2010.07919.X

Tissue inhibitor of metalloproteinase (TIMP)-2 acts synergistically with synthetic matrix metalloproteinase (MMP) inhibitors but not with TIMP-4 to enhance the (Membrane type 1)-MMP-dependent activation of pro-MMP-2.

29 August 2024

62

1 reference

https://api.crossref.org/works/10.1111/J.1742-4658.2010.07919.X

Ongoing trials with matrix metalloproteinase inhibitors

29 August 2024

63

1 reference

https://api.crossref.org/works/10.1111/J.1742-4658.2010.07919.X

Development of matrix metalloproteinase inhibitors in cancer therapy.

29 August 2024

65

1 reference

https://api.crossref.org/works/10.1111/J.1742-4658.2010.07919.X

A randomized phase II feasibility trial of BMS-275291 in patients with early stage breast cancer

29 August 2024

66

1 reference

https://api.crossref.org/works/10.1111/J.1742-4658.2010.07919.X

Tetracyclines: nonantibiotic properties and their clinical implications

29 August 2024

67

1 reference

https://api.crossref.org/works/10.1111/J.1742-4658.2010.07919.X

Antimetastatic activity of a novel mechanism-based gelatinase inhibitor

29 August 2024

68

1 reference

https://api.crossref.org/works/10.1111/J.1742-4658.2010.07919.X

Therapeutic benefits from targeting of ADAM family members

29 August 2024

69

1 reference

https://api.crossref.org/works/10.1111/J.1742-4658.2010.07919.X

Selective inhibition of ADAM metalloproteases as a novel approach for modulating ErbB pathways in cancer.

29 August 2024

70

1 reference

https://api.crossref.org/works/10.1111/J.1742-4658.2010.07919.X

Recent advances in understanding the mechanism of action of bisphosphonates

29 August 2024

71

1 reference

https://api.crossref.org/works/10.1111/J.1742-4658.2010.07919.X

Letrozole as a potent inhibitor of cell proliferation and expression of metalloproteinases (MMP-2 and MMP-9) by human epithelial breast cancer cells.

29 August 2024

72

1 reference

https://api.crossref.org/works/10.1111/J.1742-4658.2010.07919.X

A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer

29 August 2024

73

1 reference

https://api.crossref.org/works/10.1111/J.1742-4658.2010.07919.X

Estradiol-estrogen receptor: a key interplay of the expression of syndecan-2 and metalloproteinase-9 in breast cancer cells

29 August 2024

74

1 reference

https://api.crossref.org/works/10.1111/J.1742-4658.2010.07919.X

The tissue inhibitors of metalloproteinases (TIMPs): an ancient family with structural and functional diversity

29 August 2024

75

1 reference

https://api.crossref.org/works/10.1111/J.1742-4658.2010.07919.X

Neovastat, a naturally occurring multifunctional antiangiogenic drug, in phase III clinical trials

29 August 2024

76

1 reference

https://api.crossref.org/works/10.1111/J.1742-4658.2010.07919.X

Genistein inhibits p38 map kinase activation, matrix metalloproteinase type 2, and cell invasion in human prostate epithelial cells

29 August 2024

77

1 reference

https://api.crossref.org/works/10.1111/J.1742-4658.2010.07919.X

MMPs as therapeutic targets--still a viable option?

29 August 2024

79

1 reference

https://api.crossref.org/works/10.1111/J.1742-4658.2010.07919.X

Effects of angiogenesis inhibitors on multistage carcinogenesis in mice

29 August 2024

80

1 reference

https://api.crossref.org/works/10.1111/J.1742-4658.2010.07919.X

Matrix metalloproteinase inhibitors as anticancer agents

29 August 2024

81

1 reference

https://api.crossref.org/works/10.1111/J.1742-4658.2010.07919.X

Emerging roles of proteases in tumour suppression

29 August 2024

82

1 reference

https://api.crossref.org/works/10.1111/J.1742-4658.2010.07919.X

Progress in matrix metalloproteinase research

29 August 2024

83

1 reference

https://api.crossref.org/works/10.1111/J.1742-4658.2010.07919.X

Future challenges facing the development of specific active-site-directed synthetic inhibitors of MMPs

29 August 2024

84

1 reference

https://api.crossref.org/works/10.1111/J.1742-4658.2010.07919.X

Selective inhibition of matrix metalloproteinase-14 blocks tumor growth, invasion, and angiogenesis.

29 August 2024

85

1 reference

https://api.crossref.org/works/10.1111/J.1742-4658.2010.07919.X

Regulation of matrix metalloproteinase activity in health and disease

29 August 2024

86

1 reference

https://api.crossref.org/works/10.1111/J.1742-4658.2010.07919.X

Triple-helical transition state analogues: a new class of selective matrix metalloproteinase inhibitors

29 August 2024

88

1 reference

https://api.crossref.org/works/10.1111/J.1742-4658.2010.07919.X

In vivo molecular target assessment of matrix metalloproteinase inhibition

29 August 2024

89

1 reference

https://api.crossref.org/works/10.1111/J.1742-4658.2010.07919.X

Localizing matrix metalloproteinase activities in the pericellular environment

29 August 2024

90

1 reference

https://api.crossref.org/works/10.1111/J.1742-4658.2010.07919.X

Plasticity of cell migration: a multiscale tuning model

29 August 2024

91

1 reference

https://api.crossref.org/works/10.1111/J.1742-4658.2010.07919.X